InvestorsHub Logo

hoffmann6383

03/31/22 7:02 PM

#455841 RE: Lykiri #455837

another confirmation. good to know. thanks for sharing lykiri

hope4patients

03/31/22 8:09 PM

#455847 RE: Lykiri #455837

Wow. Dr Linda Liau directly contradicting Exwannabe. Who would have thunk it. :)

newman2021

03/31/22 8:27 PM

#455855 RE: Lykiri #455837

Dr. Bala/Lykiri, I missed the Miami presentation today as I was driving. If possible/available, can you please please share the slide that she talked about the SAP for the CROSSOVER ARM with the ECA? Thanks a million!

Dr Bala

03/31/22 8:48 PM

#455866 RE: Lykiri #455837

Thanks for that significant quote at the end. The peddlers of the post-hoc-SAP theory have been silenced by LL.

Evaluate

04/01/22 2:10 AM

#455901 RE: Lykiri #455837

I agree, interesting presentations today at the University of Miami by Dr. Liau.

Slide : Statistical analysis plan (SAP) for RCT with cross-over arm.
Linda Liau:
Quote:
"Before the trial was unblinded this was the statistical analysis plan that was submitted to the FDA."

this one?
Slide 23 at 3'58?
Statistical analysis plan (SAP) for RCT with cross-over arm.

eagle8

04/01/22 4:48 AM

#455909 RE: Lykiri #455837


Quote:
She went more in-depth into the details of the SAP with external control arms.


Dr Bala,

I agree, interesting presentations today at the University of Miami by Dr. Liau.

Slide : Statistical analysis plan (SAP) for RCT with cross-over arm.
Linda Liau:
Quote:
"Before the trial was unblinded this was the statistical analysis plan that was submitted to the FDA."




Thank you Lykiri.

This clearly shows, in my view, that the new endpoints and the comparison with external Placebos have been accepted by the FDA!
Not very nice for the cabal overhere.

Thanks again and best to you.